Adkins_DEA 344

November 3, 2010 To Whom It May Concern: I am writing regarding the proposed changes to docket DEA-2010-0023--Listing of Dronabinol from Schedule I to Schedule III I support the proposed action to expand the schedule III listing to include formulations having naturally-derived dronabinol and products encapsulated in hard gelatin capsules. I feel that this proposal covers many of the concerns the public would have when it comes to moving a substance from schedule I to III. The proposal states that the DEA had set up many scheduling review documents based on petitions they received from four drug companies. The proposal also states the the submissions were reviewed by the Department of Health and Human Services (DHHS). DHHS supported findings that this proposal should be adopted by the FDA. Along with this support of government agencies the proposal also discusses the regulatory certifications associated with this proposed rule. I think that it is important that generic forms of Marinol be made available to patients who use the drug for aliments resulting from treatments for cancer and AIDS. According to ProCon.org the cost of Marinol is almost $700 a month. Hopefully a generic form of dronabinol would assist those who use this drug with their exponential medical bills. From what I understand Marinol is the only drug available to treat ailments resulting from these treatments such as nausea and low appetite. If there is only one form of the drug that is available then they have a monopoly on the market and the generic brands should be able to have the same rights to produce the drug. http://medicalmarijuana.procon.org/view.answers.php?questionID=91